Dura purchase of cystic fibrosis product distributor Scandipharm will increase respiratory sales force to 330.

Executive Summary

DURA PURCHASE OF SCANDIPHARM WILL INCREASE SALES FORCE BY 50, swelling the company's respiratory products promotional force to 330 reps, on target for its planned increase to 350. Dura had a sales force of 140 in August 1996 before acquiring the rights to the antibiotics Keftab (cephalexin) and Ceclor CD (extended-release cefaclor) from Lilly ("The Pink Sheet" Aug. 26, 1996, T&G-3). Ceclor CD increased from a 17% share of the oral solid cefaclor market to 22% in the course of the third quarter, Dura said.